Lamivudine/tenofovir disoproxil fumarate - Mylan

Drug Profile

Lamivudine/tenofovir disoproxil fumarate - Mylan

Alternative Names: CIMDUO; Tenofovir disoproxil fumarate/lamivudine - Mylan

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mylan Laboratories Limited
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered HIV infections

Most Recent Events

  • 05 Mar 2018 The label for lamivudine/tenofovir disoproxil fumarate contains a boxed warning for post-treatment acute exacerbations of hepatitis B
  • 02 Mar 2018 Mylan intends to launch lamivudine/tenofovir disoproxil fumarate in USA in Second quarter of 2018
  • 28 Feb 2018 Registered for HIV infections (Combination therapy, In adolescents, In children, In adults) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top